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Abstract
A massive outbreak of Chikungunya occurred in Bangladesh during the period of April-
September, 2017 and over two million people were at risk of getting infected by the virus. A 
prospective cohort of viremic patients was constituted and analyzed to define the clinical, 
hematological and long-term aspects of this outbreak. A 35-day long comprehensive survey 
was conducted in two major, neighboring cities, Dhaka and Mymensingh. One-hundred and 
eighty-seven clinically proven Chikungunya cases were enrolled in the cross-sectional cohort 
study. Additionally, a smaller group of 48 Chikungunya patients was monitored for post-
infection effects for 12 months. Clinical data revealed that a combination of fever and arthralgia 
(oligoarthralgia and/or polyarthralgia) was the cardinal hallmark (97.9% of cases) of the 
infection. Hematological analysis showed that, irrespective of age groups, hemoglobin level 
significantly decreased and erythrocyte sedimentation rate remarkably increased in 
Chikungunya confirmed patients. However, the majority of the patients had a normal range of 
whole WBC and platelet counts; RBC counts for mid aged (40 – 60 years) and senior (61+ 
years) patients (especially in the females) were beyond the reference values. The post-infection 
study revealed that children had an early recovery from the infection compared to the adults. 
Moreover, post-infection weakness, successive relapse of arthralgic pain and memory 
problems were the most significant aftereffects, which had an impact on daily activities of 
patients. This study represents a comprehensive overview of clinical and epidemiological 
features of the 2017 outbreak of Chikungunya in Bangladesh as well as its chronic outcomes 
till the 12th month. It provides insights into the natural history of this disease which may help 
to improve management of the Chikungunya patients.
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Author summery
The clinical profile, epidemiology and the economic impacts during the acute phase of 
Chikungunya infection has been studied quite rigorously. However, studies regarding the 
hematological features and chronic consequences are very limited. In this study, a dataset of 
187 clinically proven chikungunya patients were analyzed for the clinical and hematological 
features at acute phase of the infection. Additionally, the long-term consequences till month 12 
after the infection were studied for a smaller group of 48 patients. Clinical data revealed that a 
combination of fever and joint pain (arthralgia) was the cardinal hallmark in the acute phase of 
the infection. Hematological analysis showed that, hemoglobin levels of the patients were 
significantly reduced and erythrocyte sedimentation rate increased remarkably. Also, RBC 
counts for mid-aged and older patients were beyond the reference values. The post-infection 
consequence study unveiled that children recovered better from the infection compared to the 
adults. Further, post-infection weakness, successive relapse of joint pain and memory problems 
were the most significant aftereffects. Overall, the infection had moderate to severe impact on 
daily activities of the respondents. This study provides insights into the clinical and 
hematological aspects of Chikungunya infection during the acute phase as well as describes an 
account for its chronic outcomes which puts forward to the knowledge for clinicians and 
epidemiologists regarding the infection diversity and to help improved patient management.
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1 Introduction 
2 Chikungunya is a neglected tropical disease, usually endemic to Africa, Southern and 
3 Southeast Asia. This disease is caused by the Chikungunya virus (ChikV), a classical arbovirus 
4 which possesses a single stranded positive-sense RNA genome that is transmitted to human 
5 through the bites of infected female Aedes mosquitoes, predominantly by Aedes aegypti and 
6 Aedes albopictus [1-4]. In classical Chikungunya, after a short incubation period of about 1 to 
7 5 days, acute commencement of fever and polyarthralgia, most eminently affecting the limb 
8 extremities, are the most frequently reported clinical signs in 72-97% of cases [1, 3, 5]. Other 
9 symptoms include skin rash, headaches, back pain, myalgia and nausea [2, 6, 7]. Joint pain can 
10 often be severe and may remain indefatigable for weeks to years. The most severe forms of the 
11 disease which have been reported are associated with neurological, cardiovascular, hepatic, 
12 dermatological or respiratory symptoms along with miscarriages and neonatal infections [8-
13 14]. Despite the fact that only few patients require hospitalization, there have been a few reports 
14 of fatalities due to this infection [15-18]. The clinical manifestations of Chikungunya are often 
15 confused with Dengue, especially in regions where both diseases can have outbreaks. 
16 Till now, outbreaks of Chikungunya have been reported in more than 60 countries [7]. 
17 The first Chikungunya outbreak in Bangladesh was recognized in 2008 in two villages of 
18 northwestern Bangladesh [19]. Later, in November 2011, another Chikungunya outbreak was 
19 reported in Dhaka [20]. The most dangerous outbreak of Chikungunya in Bangladesh was 
20 reported in April – September 2017, when a huge number of positive cases were reported from 
21 23 districts of the country; 13000 clinically confirmed cases were documented in the city of 
22 Dhaka alone [21-27]. The ChikV from the 2017 outbreak in Dhaka was found to be genetically 
23 distinct from the strain found in the previous outbreak, Bangladesh/0810atw [28]. Phylogenetic 
24 analysis revealed that the outbreak strains constituted a new cluster within the Indian Ocean 
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25 clade, suggesting that they are novel variants [29]. Together with variability in symptoms, 83% 
26 of patients in Dhaka also had low to very low overall quality of life, and ~30% patients had 
27 ambulatory problems due to severe arthropathy [30]. However, the impact of ChikV on 
28 hematological parameters and its long-term effects have not yet been studied. In this study, 
29 hematological parameters were assessed during the Chikungunya 2017 outbreaks in a cohort 
30 of 187 patients; a subgroup of these was continuously followed afterwards to better understand 
31 the long-term effects.
32 Materials and Methods
33 Patient recruitment, sample collection and data analysis
34 During the period of June 30, 2017 to August 4, 2017, 187 clinically confirmed, RT-
35 PCR or serological test positive patients from Dhaka and Mymensingh were recruited 
36 randomly in this study (Fig 1). A cross-sectional study was done to investigate the clinical, 
37 biochemical and hematological profiling, and a long-term follow-up was conducted to 
38 understand the after effect of Chikungunya on the quality of life. Only clinically proven 
39 Chikungunya patients were included; patients with respiratory and cardiovascular symptoms, 
40 previous report of arthralgia, any kind of arthritis, rheumatism, any major recent injuries or 
41 blood disorders were excluded from the study. Patients with proven evidence of previous or 
42 present infection by Dengue virus were also not included in the study. Among the 187 enrolled 
43 patients, 48 were found willing to follow a long-term monitoring scheme of 12 months (Long 
44 term consequence assessment group; LCA) (Fig 1). 
45 Fig 1: A schematic illustration of key features and work flow for the study.
46 Ethics Statement
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47 The methodology and protocol used for this study was reviewed and endorsed by the 
48 Graduate Research Ethics Committee, (Headed by the Dean) School of Life Sciences, Shahjalal 
49 University of Science and Technology. All participants or their legal representative gave 
50 written informed consent according to the Declaration of Helsinki. 
51 Sero-biochemical and long-term effect study
52 Biochemical and serological test results were collected after they were prescribed and 
53 performed by a specialist physician and a specialist diagnostic center respectively. Relative 
54 intensity of joint pain was evaluated using a numerical rating (NR) scale starting from 0 to 10. 
55 A rating of 0 indicated that the individual had no joint pain, and a rating of 10 indicates 
56 intolerable joint pain. Using these relative scores given by the patients, the pain intensity was 
57 categorized as mild (NR 1 – 4), moderate (NR 5 – 7) and severe (8 – 10). The anatomical 
58 location(s) of the pain and how long it existed after ChikV infection were also documented. 
59 For long-term consequences assessment (LCA) of the after-effect of Chikungunya, consented 
60 patients were interviewed with a standard questionnaire 2, 4, 6, 9 and 12 months after the 
61 viremic phase (M2, M4, M6, M9 and M12) (S2 Questionnaire). Data were analyzed using 
62 SPSS (Statistical Package for Social Sciences) and statistical significance was tested using both 
63 one-tailed and two-tailed experiments including Student T-test, z statistic, χ2 test and 
64 McNemar tests (for matched pairs of subjects) at a 99% (p = 0.01) and 95% (p = 0.05) 
65 confidence level. 
66 Results
67 Features of the patient’s cohort
68 Among the 187 confirmed (using RT-PCR and/or immunological techniques) 
69 Chikungunya (Table 1) patients, 117 (62.6%) patients were from the Dhaka region, while 70 
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70 (37.4%) were from Mymensingh. Interestingly, 18 patients from Mymensingh reported that 
71 they travelled to Dhaka in the weeks before the inclusion. The age range of ChikV positive 
72 patients was between 3 and 84 years, with the majority of cases involving the age group 41-59 
73 years (Fig 2). Also, 32 children (≤15 yrs) were included in this study.
74 Fig 2: Age and gender distribution of the sample pool.
75 Table 1: Diagnostic outcomes of sero-samples 




Total number of patients 187 (100%) 47 (100)
By Immunochromatography 135 (72.2%)
By IgM ELISA 48 (25.7%)
By both immunochromatography and IgM ELISA 4 (2.1%)
LCA: Long-term consequence assessment; n: number of respondants 
76 Demographic Data
77 Randomly collected samples and demographic data analysis revealed that females were 
78 more prone to Chikungunya (M:F=1:1.34) (Table 2). Among 187 patients, 2 were admitted to 
79 a hospital and most of the patients visited doctors and/or a diagnostic center within, on average, 
80 5.1 days after the first symptoms. 
81 Table 2: Demographic features of ChikV positive patients




Male: Female (Ratio) 1:1.34 1:1.04
Mean years of age ± Standard Deviation (Female) 38.5 ± 15.56 33.42 ± 8.52
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Mean years of age ± Standard Deviation (Male) 29 ± 17.58 33.44 ± 11.42
Time from onset to diagnostic center visit (Mean days ± 
Standard Deviation)
5.1 ± 2.9 4.8 ± 2.6
Hospitalization 2 (0.54%) 0 (0.0%)
LCA: Long-term consequence assessment
82 Signs, Symptoms and Clinical Features
83 The symptoms of ChikV infected patients are presented in Table 3.  The most common 
84 feature of the ChikV infection was high fever (39.88°C on average) and arthralgia, found to be 
85 present in ~98% of patients. Arthralgic pain was more frequently reported between day 1 to 3 
86 in the infected persons, while fever was more prominent at day 4 or 5, myalgia between days 
87 4 to 6, skin rashes between 6 to 7 days and itching on day 7. Other noticeable symptoms 
88 included swelling, stiffness and redness of joints, itching, headache, cough, insomnia, fatigue 
89 and dizziness. 
90 Table 3: Signs and symptoms recorded from ChikV positive patients during acute phase





Continuous pain 72.72 18.5
Myalgia 68.8 8
Swelling of joints 72.9
Stiffness of joints 52.1
Redness of joints 27.1 3
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Symmetrical trend of pain 62.5
Pain-fever correlation 52.1
Headache 62.5b
Enophthalmos/eye irritation/pain 3.7 4
Redness of eye 64.17 3
Throat pain 18.75 4
Sore in mouth/oral ulcer 29.2 5
Dizziness 58.3
Dysentery-like symptom 52.1c 
Fatigue 54.2







91 a~2/3rd reported continuous fever
92 b1/3rd reported severe and continuous headache
93 chalf of the patients had dysentery during the whole course of disease
94 Arthralgia was observed at 12 different anatomical sites (Fig 3), with hand joints 
95 (fingers and wrist), leg joints (ankle, knee and feet), and shoulder and neck joints being most 
96 often affected in the Chikungunya patients. Importantly, arthralgia was typically symmetrical. 
97 The intensity of the pain was stronger when patients tried to move. None of the patients 
98 reported arthralgia specific to a single anatomical site. Other signs and symptoms which were 
99 less frequent included gastrointestinal (GI) and respiratory (RD) complaints.
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100 Fig 3: Sites of pain due to Chikungunya infection
101 The signs and symptoms pattern of Chikungunya seemed remarkably different in 
102 children compared to adults (Table 4). Arthralgia was less present while vomiting was more 
103 frequently reported in children. In addition, the frequency of skin rash was notably higher.






Symptoms at onset (day 0 – day 7)
Arthralgia 87.5 100 < 0.0001
Headache 84.4 57.4 < 0.0001
Rash 37.5 87.7 < 0.0001
Itching 43.75 76.1 < 0.0001
Vomiting 64.25 25 < 0.0001
Symptoms at day 60
Arthralgia 15.6 37.5 < 0.0001
Headache 00.0 8.33 < 0.0001
Vomiting/vomiting tendency 00.0 10.4** < 0.0001
105 *Calculated from t-test
106 **All respondents were females
107 Hematological Findings
108 Hematological analysis of ChikV positive patients revealed that hemoglobin level was 
109 significantly low in both children and adults compared to standard reference value (Table 5). 
110 For ChikV positive patients, the complete white blood cell (WBC) counts ranged from 2 to 
111 12.6 K/μL, of which neutrophil (NTP) counts ranged between 32-80% and lymphocyte (LPC) 
112 counts ranged between 14 – 56%. Platelet counts ranged from 85 K/μL to 547 K/μL. Although 
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113 the majority of the ChikV positive patients were within normal ranges for whole WBC, 
114 neutrophils, LPC and platelets (PLT), many patients represented varying degrees of 
115 lymphopenia when compared to reference values (Fig 4). 
116 Table 5: Hematological findings in ChikV positive patients according to age groups








Hemoglobin level in g/dL (Reference range for male: 12 – 17 g/dL, female: 11.5 – 15.5 g/dL)
Children (1 - 15) 11.55 7.82 - 15.2 12 (37.5) 20 (62.5) 0.015822
Young (16 - 25) 13 9.5 - 15.6 19 (79.17) 5 (20.83) 0.001546
Mid Aged (26 - 40) 12.4 8.9 - 15.6 37 (63.79) 21 (36.21) 0.002727
Seniors (41 - 59) 12.1 8.1 - 14.9 27 (44.26) 34 (55.74) 0.012039
Old (60+) 10.55 9 - 13.2 5 (41.67) 7 (58.33) 6.20e-05
Total 100 (53.48) 87 (46.52)
ESR in mm in 1st hour (Reference range for male: 0 - 10 mm in 1st hour, female: 0 - 20 mm in 1st hour)
Children (1 – 15) M: 23, F: 25 4 - 164 8, 25) 24 (75) < 0.00001
Young (16 - 25) M: 30, F: 23 3 - 60 12 (50) 12 (50) < 0.00001
Mid Aged (26 - 40) M: 12, F: 24 3 - 111 20 (34.48) 38 (65.52) < 0.00001
Seniors (41 - 59) M: 13.5, F: 28 5 - 103 13 (21.31) 48 (78.69) < 0.00001
Old (60+) M: 16.5, F: 31 12 - 101 1 (8.33) 11 (91.67) -
Total 54 (28.88) 133 (71.12)
RBC count in M/µL (Reference range: 4.2 – 6.2 M/µL)
Children (1 - 15) 4.4 3.7 - 5.66 27 (84.38) 5 (15.62) 6.9e-05
Young (16 - 25) 4.8 3.9 - 5.65 21 (87.50) 3 (12.50) < 0.00001
Mid Aged (26 - 40) 4.6 3.8 - 6.4 11 (18.97) 47 (81.03) 0.415072
Seniors (41 - 59) 4.4 3.2 - 6.22 17 (27.87) 44 (72.13) 0.251382
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Old (60+) 4.2 3.4 - 4.38 8 (75) 4 (25) 0.296948
Total 84 (44.92) 103 (55.08)
WBC count in K/µL (Reference range: 4.8 – 10.8 K/µL)
Children (1 - 15) 6.725 4 - 12.2 17 (53.12) 15 (46.88) 0.895775
Young (16 - 25) 6 4.4 - 10.5 18 (75) 6 (25) < 0.00001
Mid Aged (26 - 40) 6 3.7 - 12.5 39 (67.24) 19 (32.75) 0.929082
Seniors (41 - 59) 5.9 2 - 12.6 40 (65.57) 21 (34.43) 0.530659
Old (60+) 8 3 - 10.6 8 (75) 4 (25) < 0.00001
Total 122 (65.24) 65 (34.76)
Neutrophil part in % (Reference range: 40 – 70 %)
Children (1 - 15) 57.5 37 - 72 29 (90.63) 3 (9.37 0.675216
Young (16 - 25) 61.5 32 - 80 14 (58.33) 10 (41.67 0.269463
Mid Aged (26 - 40) 64 40 - 80 47 (81.03) 11 (18.97 0.005389
Seniors (41 - 59) 62 52 - 75 58 (95.08) 3 (4.92 < 0.00001
Old (60+) 66.5 46 - 75 10 (83.33) 2 (16.67 < 0.00001
Total 158 (84.50) 29 (15.50)
Lymphocyte part in % (Reference range: 20 – 45 %)
Children (1 - 15) 35 23 - 55 29 (90.63) 3 (9.37) < 0.00001
Young (16 - 25) 27.5 15 - 52 18 (75) 6 (25) 0.985798
Mid Aged (26 - 40) 30 14 - 56 46 (79.31) 12 (20.69) 0.871306
Seniors (41 - 59) 33 17 - 42 60 (98.36) 1 (1.64) -
Old (60+) 28 17 - 42 11 (91.67) 1 (8.33) -
Total 164 (87.70) 23 (12.29)
Platelets count in K/µL (Reference range: 150 – 500 K/µL)
Children (1 - 15) 263.5 115 - 505 29 (90.63) 3 (9.37 0.883132
Young (16 - 25) 226.5 135 - 515 21 (87.5) 3 (12.5 0.871306
Mid Aged (26 - 40) 229 150 - 547 56 (96.55) 2 (3.45 < 0.00001
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Seniors (41 - 59) 255 85 - 465 59 (96.72) 2 (3.28 < 0.00001
Old (60+) 242.5 168 - 372 12 (100) 0 (0) -
Total 177 (94.65) 10 (5.35)
117 M = Male, F = Female.    *Calculated from z score.
118 However, at the onset of the disease, no significant correlation was observed between 
119 the level of leukocytopenia and the intensity of arthralgic pain. Red blood cell (RBC) count 
120 was remarkably above the reference range in the mid aged and senior groups. The interquartile 
121 range of the RBC was between 3.2 to 6.22 M/μL and the median value was 4.5 M/μL. 
122 Erythrocyte sedimentation rate (ESR) was significantly higher in all age groups, especially in 
123 female patients (Table 5). Further, a significant correlation was obtained between the different 
124 age groups and RBC counts, neutrophil counts and leucocyte counts of the ChikV positive 
125 patients (S3 Table). 
126 Fig 4: Scatter diagram of hematological findings of ChikV positive patients. Shadowed area 
127 denotes the reference ranges. a) Haemoglobin level in females. b) Haemoglobin levels in 
128 males. c) RBC counts in females. d) RBC counts in males. e) WBC counts in females. f) WBC 
129 counts in males. g) Platelet counts in females. h) Platelet counts in males
130 Characteristics of long-term arthralgia in ChikV infected patients 
131 Long-term arthralgia associated with ChikV infection. All patients enrolled in the LCA 
132 group were interviewed using a questionnaire at M2, M4, M6, M9 and M12 post-ChikV 
133 infection to monitor persistence of fever, arthralgia and other clinical symptoms. None of our 
134 monitored patients reported a relapse of the fever. The percentage of patients suffering from 
135 long-term arthralgia decreased significantly (till M6) after the acute phase of the infection and 
136 then raised to ~19% at M9 and M12. Most of our enrollees complained of intermittent 
137 arthralgia, with successive recovery and relapse; none of the patients complained of permanent 
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138 arthralgia at any timepoint after the acute phase and all of the respondents reported that the 
139 intensity of the pain was significantly reduced after M2. Of note, all of our enrolled patients in 
140 the LCA group suffered from arthralgia between day 0 to 7 and none of them suffered from 
141 joint pains prior to the ChikV infection. The McNemar test for matched pairs of subjects 
142 revealed that the site of arthralgic pain (S4 Table) remained the same at each time point. The 
143 percentage of patients suffering from myalgia decreased a lot after the acute phase of the 
144 infection and stabilized by M6. None of the patients reported to have myalgia at M9 and M12 
145 (Fig 5). When ChikV-induced arthralgia relapsed, it was symmetrical, involving more than 2 
146 different anatomical locations. Most frequently, the finger joints, wrists and ankles were 
147 affected; regardless of age and sex, some patients complained of pain at elbow joint and knee.  
148 Fig 5: Persistence of Chikungunya symptoms over time course in ChikV positive patients     
149 We noted that the number of sites affected by arthralgia gradually diminished in patients 
150 still suffering until M2, with only 23% patients suffering from polyarthralgia. However, the 
151 number of anatomical locations further decreased significantly in M4 and M6 and then 
152 stabilized at M9 and M12 (50% and 64% respectively, p value < 0.0001). 
153 Other long-term clinical signs associated with ChikV infection. At M6, M9 and M12, the 
154 LCA group displayed other symptoms including local swelling of joints, cutaneous and 
155 dermatological symptoms and post-infection weakness. Additionally, sleep, memory and/or 
156 concentration disorders as well as depression and stinginess were remarkably associated. 
157 Furthermore, between M6 and M12, 16.67% (n = 8) complained that they frequently suffered 
158 tachycardia during working, even though none of them had any previous heart complications. 
159 The number of patients who visited a physician increased significantly between M6 (4; 
160 8.33%) and M12 (16; 33%, data not shown) (p < 0.005). However, the most significant after-
161 effect of the infection in our study population appeared to be post infection weakness. Around 
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162 40% of the patients reported to have continuous weakness at M2. The percentage decreased 
163 significantly at M6, increasing however again to ~17% at M9 and M12. Besides, more than 
164 20% of patients complained about sleep disorder at M2 and M4, but the percentage diminished 
165 to less than 10% at M6. However, complaints of disturbed sleep slightly increased at M9 and 
166 M12 (Fig 5). 
167 Over 10% of patients complained of new symptoms at M2 which they had not suffered 
168 from during the acute phase of the infection (Fig 5). Even at M6, 6.25% patients reported to 
169 suffer new symptoms and more than 4% patients to experience new symptoms at M9. However, 
170 we did not attempt to find any association between the newly gained symptoms and the effect 
171 of the RNA virus infection. Although the new symptoms were generally sleeping problems, 
172 swelling of joints, arthritis-like symptoms and memory problems were also reported. Although 
173 the respondents did not display any neurological dysfunction, the mild memory problems could 
174 not be excluded to result from the ChikV infection. Some of the patients reported that they 
175 were frequently prone to depression and partially lost control over their temper. 
176 Post infection impact on daily life at M6 and M12
177 Arthralgia coupled with weakness in patients at M6 and M12 were highly incapacitating 
178 for daily life activities, professional life and leisure activities (Table 6). Most of the patients 
179 having chronic arthralgia complained of pain when rising from sitting and lying, walking or 
180 picking up a load. Twenty-seven percent and ~23% patients respectively in M6 and M12 
181 reported that the arthralgia affected their professional activities. Remarkably, ~31% patients 
182 complained that arthralgia had disturbed them in leisure. Moreover, all the patients having 
183 memory problems complained that it had significant impact on their day to day life activities. 
184 Table 6: Impact of arthralgia on daily life for patients at M6 and M12
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M6 (%) M12 (%)
Issues regarding quality of life
    Discomfort while rising from sitting/lying 22.91 16.67
    Weakness in long walks (over 1 KM) 10.41 8.33
    Discomfort during picking up a heavy object 20.83 18.75
    At least one of these discomforts 29.17 25
Impacts on working life
    With activity 27.1 22.91
    Physical impact 22.91 10.41
        low impact 54.54 55.55
        moderate impact 27.27 22.22
        high impact 18.18 22.22
Impact on leisure-time
    No impact 66.67 62.5
    Physical impact 33.33 29.17
        low impact 18.75 35.71
        moderate impact 31.25 28.57
        high impact 50 35.71
M: month
185 Discussion
186 The Chikungunya outbreak of 2017 in Bangladesh appeared as an epidemic 
187 manifestation with 23 of 65 districts of the country infected. This study presents clinical and 
188 epidemiological data of this Chikungunya outbreak. 
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189 Bangladesh is a riverine monsoon country, and as such an ideal vicinity for the 
190 emergence of arboviral diseases including Dengue and Chikungunya. As both have 
191 overlapping pathophysiological mechanisms and proceed simultaneously, it is real challenge 
192 for physicians to distinguish among them, especially during the early stages of infection [30].
193 ChikV was found to infect all ages and both sexes; however, ratios varied. A higher 
194 percentage of cases was observed in adult females (56.7%) than males (38%) and female 
195 children (43.3%). This is different from previously reported ratios for the Asian lineage where 
196 male cases were more frequent [30-34], except for the reports from Pakistan where females 
197 were more prone to be infected by the ChikV [35]. The higher percentage of adult female cases 
198 may be due to higher levels of exposure to infected vectors in the home environment, since 
199 Bengali women spend more time at home and the mosquitoes are commonly found indoors 
200 [36-39]. In addition, mosquitoes can trace estrogen which works as a lure and since females 
201 exhibit higher levels of estrogen, mosquitoes tend to bite them more [40-41]. The difference in 
202 number of cases in the age groups may not reflect vulnerability of any specific group but 
203 indicate the general population structure in the country [42], i.e. the infection trend was not 
204 biased to any age group.
205 Irrespective of sex, the combination of fever and severe arthralgia (present in 97.9% of 
206 cases) can be regarded as the cardinal hallmark of the Chikungunya 2017 outbreak in 
207 Bangladesh. This is consistent with the previous outbreak report (83.3 to 98%), though the 
208 values were less in case of the children [31, 43-45] (Table 2, Table 3). However, in an Indian 
209 outbreak of the virus in Kerala in 2007, arthralgia was found to be the initial symptom in only 
210 ~17% patients [33]. 
211 We found a symmetrical presentation of arthralgia in most of the cases (62.5%), while 
212 a higher percentage of patients reported polyarthralgia (56.25%) than oligoarthralgia (43.75%). 
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213 In addition, we observed that finger joints (93.8%) and wrist (85.4%) joints were the most 
214 affected sites. In the acute phase, the frequency of incapacitating pain involving certain 
215 peripheral joints (Fig 3) was found to be comparable with the study of Queyriaux et al. 2008 
216 and Staikowsky et al. 2008; however, it contrasted with earlier reports from India and Suriname 
217 [33, 46-49].
218 Other symptoms including headache, itching, catarrh-cough, dizziness, and dysentery 
219 were found to be similar to most of previous studies, except for an unusually high frequency 
220 of rash (79.2%), swollen joints (72.9%) and redness of eye (64.17%) in the present study [50]. 
221 Over 85% of the patients complained of severe pain with a median NRS score of 9 
222 throughout the acute phase, which was similar as the findings of Staikowsky et al. 2008 [47]. 
223 Almost two-thirds (64.6%) of our enrolled patients faced sleep disturbances due to arthralgia 
224 and myalgia (Table 3). The rate of hospitalization (2.1%) was very low and the outbreak did 
225 not cause any fatal outcomes. Nonetheless, the overall severity and the extent of arthralgia-
226 related manifestations suggest that an aggressive strain of Chikungunya virus probably 
227 circulated during the outbreak.
228 The severity of certain clinical manifestations of Chikungunya might depend on several 
229 factors including age, gender, immune status, genetic predisposition etc. [51]. Our analysis 
230 showed that children (<15 years) had a lower tendency to have skin rash and itching as well as 
231 vomiting. Conversely, a significantly higher frequency of headache was observed among the 
232 children compared to other age groups. The duration of pain and rate of any relapse of post-
233 infection symptoms were significantly lower among children as compared to other age groups 
234 (Table 4). 
235 With regards to hematological parameters, distinct markers are yet to be found. Lee et 
236 al. (2012) documented several predictable laboratory tests for detecting ChikV, e.g. a drop in 
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237 lymphocyte count and a higher count of platelets, leukocytes and neutrophils [52]. In our study, 
238 a difference in the hematological findings was documented across all age groups. For instance, 
239 hemoglobin level was significantly lower in children and older patients; however, RBC counts 
240 were significantly above the reference range in mid-aged and senior groups. We were not able 
241 to document any significant drop in the lymphocyte counts nor any significant increase in 
242 platelets, leucocytes or neutrophils counts. These outcomes are atypical when compared to the 
243 reports from the Ahmedabad outbreak, the Caribbean outbreak in Trinidad in 2015, the La 
244 Romana outbreak in 2016 and the Kandy outbreak in Sri Lanka in 2006-07 [31, 44, 53-54]. 
245 However, the ESR values obtained through our analysis reports a very broad range with 
246 significantly elevated rates in most cases across age and sex (p <0.00001) (Table 5). 
247 Based on the follow-up of patients with acute ChikV infection who consented to 
248 participate, this study shows the evolution of arthralgia, mapping the frequency and location of 
249 arthralgic sites during a 12-month time period. Our data reveals that the proportion of patients 
250 having ChikV-induced arthralgia decreased at an almost constant rate at each timepoint (Fig 
251 5). Myalgia was not a complaint anymore at M6 and thereafter. This is different compared to 
252 the higher percentage of patients with long-term symptoms was reported by several studies of 
253 Italian and French cohorts of La Re´union Island or metropolitan France [43, 55-57]. Till M12, 
254 ChikV-induced arthralgia was mainly symmetrical, and finger joints, wrist, ankle and knee 
255 were found to be most affected; this remains consistent with other studies [43, 54]. 
256 There is evidence from different countries - especially France, India, Sri Lanka, 
257 Malaysia, Colombia, Venezuela and USA - to suggest that sudden rise of heart rate was 
258 associated with the infection at both the acute and the chronic phases [58]. In our cohort, 
259 cardiovascular manifestations were not reported by patients during the acute phase and till M6. 
260 However, 16.67% of the patients experienced abnormal heart rates between M6 and M12. 
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261 Alvarez et al. underlined the urgent need to explore the cardiovascular impact of a ChikV 
262 infection in 2017 [58]. To date, these effects remain to be elucidated. 
263 Weakness during professional activities was noted to be the most prominent after effect 
264 of the infection, as almost 40% of our patients reported to have severe weakness at M4. The 
265 proportion diminished over time but relapsed several times in some patients till M12. In 
266 addition, many patients complained from disturbed sleep, swelling of joints and suffered new 
267 symptoms, e.g. memory problems. Although the patients in our study did not display any 
268 significant neurological symptoms at the acute phase of disease, we were unable to exclude 
269 that these memory problems during the chronic phase resulting from ChikV spread in the 
270 central nervous system, as it had been reported that ChikV disseminates to the central nervous 
271 system in humans and in animals [59-62]. As was obvious in other studies, chronic ChikV 
272 induced complications are considered incapacitating for daily life tasks and impact professional 
273 activities and quality of life [56-57]. 
274 While the previous studies concerning Chikungunya Outbreak 2017 in Bangladesh 
275 were limited within the samples recruited from Dhaka only, this study represents a diverse 
276 sample population [30, 51]. In addition, our study was extended to the hematological and 
277 chronic outcomes of the outbreak rather than to be confined only within the study of clinical 
278 and quality of life parameters [30]. However, this study is not free from any limitations. This 
279 recruited only the clinically confirmed cases of Chikungunya, but the studied sample pool was 
280 relatively smaller than the previous study [30, 51]. Hossain et al., 2018 reported that, the 
281 representation of clinically confirmed cases of ChikV was very low during the 2017 outbreak 
282 in Bangladesh due to the high cost of testing and scarcity of diagnostic facilities [30], which 
283 might be an explanation behind the recruitment of this smaller sample pool. Moreover, data 
284 regarding the clinical, chronic impact and daily life related parameters were collected through 
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285 retrospective technique, which might be prone to recall bias. Further, it is not unlikely that 
286 some respondents have overvalued some clinical symptoms due to the psychological impacts 
287 of massive social media coverage of the outbreak. But this study was conducted during the 
288 very peak of the outbreak and the patients were monitored and interviewed rigorously at regular 
289 intervals, we assume the recall bias was minimized.
290 In summary, this study alludes to the clinical and epidemiological characteristics of the 
291 Chikungunya outbreak of 2017 in Bangladesh. It facilitates our comprehension of the 
292 pathophysiology of the disease across age groups and its chronic consequences till M12, a 
293 prerequisite for the development of efficient management and therapeutic strategies and for 
294 assessing the damage inflicted upon the population by a Chikungunya outbreak. 
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